Skip to main content

Pharmacovigilance of Alternative Medications in the Cancer Setting

  • Chapter
  • First Online:
Cancer Policy: Pharmaceutical Safety

Part of the book series: Cancer Treatment and Research ((CTAR,volume 171))

Abstract

With the increase in utilization of alternative medications to manage cancer treatment-related side effects, pharmacovigilance of alternative drug therapies, specifically herbal supplements, has become of increasing importance in the oncologic setting. This chapter focuses on the pharmacovigilance of herbal supplements in the setting of cancer drug therapy and explores national and international drug policies that have been employed to mitigate adverse herbal supplement events (AHEs). This chapter examines common drug-herbal supplement interactions, discusses the mechanisms behind these interactions, and investigates several common pharmacovigilance reporting methods clinicians can use to report adverse events. This chapter will also describe policies and strategies that can be employed to monitor use of these alternative drug therapies, and examines global harmonization efforts to reduce AHEs in the cancer setting. The safety of herbal medicines has emerged as an international public health priority, and we explore how oncology providers may directly apply the knowledge garnered herein to help guide their clinical management of oncology patients utilizing alternative medications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pharmacovigilance. Available at http://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/.

  2. Hazell L, Shaki SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–6.

    Article  Google Scholar 

  3. Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013;36(2):75–81.

    Article  Google Scholar 

  4. Varallo FR, Guimarães Sde O, Abjaude SA, Mastroianni Pde C. Causes for the underreporting of adverse drug events by health professionals: a systematic review. Rev Esc Enferm USP. 2014;48(4):739–47.

    Article  Google Scholar 

  5. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Tharakan ST, Sung B, Anand P. Potential of spice-derived phytochemicals for cancer prevention. Planta Med. 2008;74:1560–9.

    Article  CAS  Google Scholar 

  6. Kasliwal R. Spontaneous reporting in pharmacovigilance: strengths, weaknesses and recent methods of analysis. J Clin Prev Cardiol. Available at http://www.jcpcarchives.org/full/spontaneous-reporting-in-pharmacovigilance–strengths-49.php.

  7. Guidance Document for Industry—Reporting Adverse Reactions to Marketed Health Products. Available at https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/medeffect-canada/guidance-document-industry-reporting-adverse-reactions-marketed-health-products-health-canada-2011.html.

  8. Increased use of oral chemotherapy drugs spurs increased attention to patient compliance. J Oncol Pract. 2008;4(4):175–7. https://doi.org/10.1200/jop.0843002.

  9. Partridge AH, Avorn J, Wang PS, et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652–61.

    Article  Google Scholar 

  10. Weingart SN, Brown E, Bach PB, et al. NCCN task force report: oral chemotherapy. J NCCN. 2008;6:S1–15.

    Google Scholar 

  11. Fasinu PS, Bouic PJ, Rosenkranz B. An overview of the evidence and mechanisms of herb-drug interactions. Front Pharmacol. 2012;30(3):69. https://doi.org/10.3389/fphar.2012.00069.

    Article  Google Scholar 

  12. Borrelli F, Izzo A. Herb-drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations. AAPS J. 2009;11:710.

    Article  CAS  Google Scholar 

  13. Frye RF, Fitzgerald SM, Lagattuta TF, et al. Effect of St John’s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther. 2004;76:323–9.

    Article  CAS  Google Scholar 

  14. Whqlibdoc.who.int [homepage on the Internet]. Geneva: World Health Organization. 1973. Handbook of resolutions and decisions of the World Health Assembly and Executive Board. Available from: http://whqlibdoc.who.int/wha_eb_handbooks/9241652063_Vol2.pdf.

  15. Essential Medicines and Health Products. Available at http://www.who.int/medicines/areas/quality_safety/safety_efficacy/National_PV_Centres_Map/en/.

  16. WHO guidelines on safety-monitoring of herbal medicines in pharmacovigilance systems. Available at http://apps.who.int/medicinedocs/documents/s7148e/s7148e.pdf.

  17. Herbal Medicinal Products. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000208.jsp.

  18. Dietary Supplement Products and Ingredients. Available at https://www.fda.gov/food/dietarysupplements/productsingredients/.

  19. Guidance for Industry: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, of Holding Operations for Dietary Supplement; Small Entity Compliance Guide. Available at https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/DietarySupplements/ucm238182.htm.

  20. Uppsala Monitoring Centre. Available at https://www.who-umc.org/.

  21. Shetti S, Kumar CD, Sriwastava NK, Sharma IP. Pharmacovigilance of herbal medicines: current state and future directions. Pharmacognosy Magazine. 2011;7(25):69.

    Article  Google Scholar 

  22. Committee on Herbal Medicinal Products (HMPC). Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000264.jsp.

  23. Americans Spend $30 Billion a Year Out-of-Pocket on Complementary Health Approaches. Available at https://nccih.nih.gov/research/results/spotlight/americans-spend-billions?nav=rss.

  24. Nahin RL, Barnes PM, Stussman BJ. Expenditures on complementary health approaches: United States, 2012 (433 kb pdf). National Health Statistics Reports. Hyattsville, MD: National Center for Health Statistics; 2016.

    Google Scholar 

  25. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–96 Epub 2006/05/13.

    Article  Google Scholar 

  26. Richardson M, Sanders T, Palmer J. Complementary alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18:2505–14.

    Article  CAS  Google Scholar 

  27. Hoffman KB, Demakas AR, Dimbil M, Tatonetti NP, Erdman CB. Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS). Drug Saf. 2014;37(11):971–80.

    Article  Google Scholar 

  28. Layton D, Hazell L, Shakir SA. Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management. Drug Saf. 2011;34:e1–9.

    Article  Google Scholar 

  29. Barnes J. Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part II: efficacy and safety. Br J Clin Pharmacol. 2003;55(4):331–40.

    Article  CAS  Google Scholar 

  30. Tascilar M, de Jong FA, Verweij J, Mathijssen RH. Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist. 2006;11(7):732–41.

    Article  Google Scholar 

  31. McKoy JM, Haleem AS, Liebling DB. Herbal supplements: boon or bane for older cancer patients? Available at http://ascopubs.org/doi/abs/10.1200/jco.2011.29.15_suppl.e16633.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dustin B. Liebling .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Liebling, D.B., Cordova, E., Deng, G., McKoy, J.M. (2019). Pharmacovigilance of Alternative Medications in the Cancer Setting. In: McKoy, J., West, D. (eds) Cancer Policy: Pharmaceutical Safety. Cancer Treatment and Research, vol 171. Springer, Cham. https://doi.org/10.1007/978-3-319-43896-2_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43896-2_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43894-8

  • Online ISBN: 978-3-319-43896-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics